Kalaris Therapeutics, Inc. (KLRS) vs Merck & Co., Inc. (MRK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| KLRS | MRK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq GM | NYSE |
| Country | United States | United States |
| Theme | vision-and-ophthalmology | oncology |
| Price and returns | ||
| Last close | $1.80 | $140.61 |
| Return · 1 week | −5.76% | −2.10% |
| Return · 1 month | −36.73% | −5.43% |
| Return · 3 months | −46.11% | +6.67% |
| Return · year to date | −78.31% | +33.07% |
| Return · 1 year | −62.96% | +62.34% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −84.85% | −10.39% |
| 52-week high | $11.88 | $156.92 |
| 52-week low | $1.78 | $82.01 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $42.85M | $346.91B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $104.40K | $1.24B |
| Employees | 20 | 73,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 115.56× |
| Price to earnings · forward | n/a (negative forward earnings) | 15.62× |
| Price to sales | — | 5.40× |
| Price to book | 0.97× | 8.57× |
| Enterprise value to EBITDA | — | 13.82× |
| Enterprise value to revenue | — | 6.00× |
| PEG ratio | — | 2.59 |
| Earnings per share · trailing | -1.95 | 1.26 |
| Profitability | ||
| Gross margin | — | 72.97% |
| Operating margin | 0.00% | −0.24% |
| Profit margin | — | 4.77% |
| Return on equity | −79.91% | 6.96% |
| Return on assets | −31.03% | 11.87% |
| Growth | ||
| Revenue growth | — | +5.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 2.43 | 128.41 |
| Current ratio | 10.98 | 1.32 |
| Dividend yield | 0.00% | 2.38% |
| Payout ratio | — | 266.67% |
| Trend and volatility | ||
| RSI · 14 | 21.30 | 42.46 |
| ADX · 14 | 56.87 | 16.51 |
| 50-day average | $3.11 | $146.74 |
| 200-day average | $5.55 | $126.01 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 9.21% | 3.41% |
The full KLRS analysis
Everything this table leaves out for Kalaris Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the KLRS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full KLRS analysisThe full MRK analysis
Everything this table leaves out for Merck & Co., Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK analysis